DOCSLIB.ORG

Effects of Iontophoretically Released Amino Acids and Amines on Primate Spinothalamic Tract Cells’

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Iontophoretically Released Amino Acids and Amines on Primate Spinothalamic Tract Cells’ 0270.6474/84/0403-0732$02.00/O The Journal of Neuroscience Copyright 0 Society for Neuroscience Vol. 4, No. 3, pp. 732-7480 Printed in U.S.A. March 1984 EFFECTS OF IONTOPHORETICALLY RELEASED AMINO ACIDS AND AMINES ON PRIMATE SPINOTHALAMIC TRACT CELLS’ W. S. WILLCOCKSON, J. M. CHUNG, Y. HORI, K. H. LEE, AND W. D. WILLIS’ Marine Biomedical Institute, University of Texas Medical Branch, Galveston, Texas 77550 Received June 10, 1983; Revised September 28, 1983; Accepted September 29, 1983 Abstract The effects of glutamate (Glu), y-aminobutyric acid (GABA), glycine (Gly), serotonin (5HT), norepinephrine (NE), dopamine (DA), and acetylcholine (ACh) were examined in this study by iontophoretic application onto primate spinothalamic tract (STT) neurons identified antidromically by stimulation in the contralateral thalamus. Drugs were tested for effects on background activity, Glu-induced firing, and activity evoked by pinching of the skin, Whereas Glu excited STT cells and was thus used for tests of the other compounds, the amino acids GABA and Gly inhibited Glu- and pinch-induced activity in all STT cells examined. STT cells were also inhibited by 5-HT, NE, and DA. Only two cases of excitation by 5-HT were seen (of 58 cells tested). ACh also had inhibitory actions on STT cells, although 3 of 21 cells exhibited some enhancement of activity. The effects of these compounds on identified STT cells resemble previous demonstrations of the effects of these drugs on dorsal horn interneurons. The results suggest that GABA, Gly, 5-HT, NE, and DA may be inhibitory neurotransmitters on nociceptive STT cells. A key problem to be solved concerning the processing fecting the activity of STT cells. We have demonstrated of somatosensory information is the identification of the that serotonin (5-HT) released iontophoretically near neurotransmitters that are used in the sensory pathways STT cells usually causes a depression of the background originating in the periphery, synapsing in the spinal cord discharges, the responses to noxious stimuli, and gluta- and brainstem and projecting to the thalamus and cere- mate (Glu)-evoked activity (Jordan et al., 1978, 1979). bral cortex. Of equal interest are those transmitters that However, some STT cells that have subcutaneous recep- modify transmission along the somatosensory pathways. tive fields can be excited by iontophoretically applied 5- For example, there may be practical uses of agents that HT (Jordan et al., 1979). Recently, it has been shown modulate nociceptive transmission in the spinal cord. that primate STT and trigeminothalamic tract cells la- Our laboratory has been investigating the responses of beled with retrogradely transported horseradish peroxi- spinothalamic tract neurons in the monkey (Willis et al., dase receive synaptic contacts containing enkephalin- 1974; Chung et al., 1979). The spinothalamic tract (STT) like immunoreactivity (Ruda, 1982). Thus, it would be is a major somatosensory pathway in primates, including predicted that microiontophoretically applied enkepha- humans, and it is crucial for pain sensation (White and lin might have a postsynaptic action on primate STT Sweet, 1955; Noordenbos and Wall, 1976; Vierck and cells. Luck, 1979). In addition, the STT is likely to contribute A number of putative neurotransmitters are present to temperature and tactile sensations (White and Sweet, in the spinal cord dorsal horn and have an action on 1955). dorsal horn interneurons following microiontophoretic Very little is known about the neurotransmitters af- application. These substances include the amino acids glutamic acid, glycine (Gly), and y-aminobutyric acid (GABA) (Curtis et al., 1959, 1960; 1968; Graham et al., 1 This work was supported by Grants NS 09743, NS 11255, and NS 1967; Zieglgansberger and Puil, 1973; McLaughlin et al., 18830 from the National Institutes of Health and by a grant from the 1975), the catecholamines norepinephrine (NE) and do- Moody Foundation. We wish to thank Helen Willcockson for her expert pamine (DA) (Engberg and Ryall, 1966; Zivin et al., 1975; technical assistance in the surgical preparation of the animals and in Headley et al., 1978), acetylcholine (ACh) (Engberg and the art work. We thank also G. Gonzales for her help with the histology and Phyllis Waldrop for typing the manuscript. Ryall, 1966; Zieglgansberger and Reiter, 1974; Houser et ’ To whom correspondence should be addressed, at Marine Biomed- al., 1983; however, cf., Curtis et al., 1961), and several ical Institute, 200 University Boulevard, Galveston, TX 77550. peptides, including substance P and somatostatin (Tak- 732 The Journal of Neuroscience Amino Acids and Amines on STT Cells 733 ahashi and Otsuka, 1975; Henry, 1976; Hokfelt et al., Drug concentrations and pH were as follows: L-mon- 1976), in addition to 5-HT and enkephalin. osodium-glutamate salt (Sigma), 0.2 M, pH 8.5; GABA The present study is a survey of the effects of a number (Sigma), 0.2 M, pH 3.5; Gly (Sigma), 0.2 M, pH 3.5; 5- of candidate neurotransmitters released by microionto- HT creatinine sulfate (Sigma), 50 IIIM, pH 5.0; L-nor- phoresis in the vicinity of primate STT cells. The exper- epinephrine hydrochloride (NE) (Sigma), 0.1 M, pH 4.0; iments are the initial stage of an analysis of the phar- dopamine hydrochloride (DA) (Sigma), 0.1 M, pH 4.0; macology of synaptic excitation and inhibition of these acetylcholine iodide (ACh) (Sigma), 1.0 M, pH 5.0. All neurons that are thought to play an important role in drugs were dissolved in sterile, deionized water (dH,O), pain mechanisms. The actions of amino acids and amines except NE and DA which were made up in 5 x lop5 M are described in this paper, and the actions of peptides ascorbic acid in dHzO to prevent oxidation. Glu and 5- are described in the companion paper (Willcockson et HT were dissolved 4 to 5 hr before use; all other drugs al., 1984). A preliminary report has been made (Will- were made up immediately before filling the electrodes. cockson et al., 1983a). With the exception of Glu, all compounds were applied with cationic current. Retaining currents were always Materials and Methods less than 7 nA. Current neutralization was used during all drug applications through a balancing barrel filled Experiments were performed on 19 monkeys (Mucaca with 0.2 M NaCl. fascicularis) weighing 1.9 to 3.2 kg. Animals were initially Drugs were tested on STT neurons for effects on anesthetized with a mixture of halothane, nitrous oxide, background activity, Glu-induced firing, and activity and oxygen, followed by a single dose of a-chloralose (60 evoked by innocuous (brush) and noxious (pinch with a mg/kg, i.v.). Gallamine triethiodide (Flaxedil) was used small clip) mechanical stimuli. Glu activation was to immobilize the animal and artificial ventilation was achieved by pulsed release of Glu ions (5 to 25 nA) for 5 instituted. End-tidal CO* was maintained between 3.5 set at lo-set intervals. Drugs were iontophoresed contin- and 4.5%. A supplemental infusion of sodium pentobar- uously over a 40-set period. bital (5 mg/kg/hr) and gallamine triethiodide (4 mg/kg/ Extracellular spikes were used to trigger a window hr) was given throughout the duration of the experiment. discriminator. Peristimulus time histograms were com- Rectal temperature was regulated near 37°C. piled by computer. Control responses to background, Glu, The lumbosacral spinal cord was exposed by laminec- or mechanically evoked activity were compared to re- tomy at vertebral levels L2 to L6 to allow recordings sponses during the test drug application. Percentage of from STT cells. A craniotomy at the vertex of the skull inhibition or excitation was calculated as [number of provided access to the thalamus. In three experiments impulses during test period/number of impulses during decorticate spinalized animals were used. Decortication control period) x lOO%] - 100%. was accomplished by bilateral common carotid artery At the conclusion of each experiment stimulating and ligation and spinalization by compression of the cord at recording sites were marked by passing direct current the C2 spinal level. No chloralose was given, and supple- through the electrodes. Steel electrode marks in the mental pentobarbital was omitted from the infusion in thalamus were enhanced histologically by the Prussian these animals. blue reaction. Carbon-fiber marks at STT cell locations The caudal part of the ventral posterior lateral nucleus were visible as microlesions. of the right contralateral thalamus (VPLc nucleus of Olszewski, 1952) was found by recording potentials Results evoked by electrical stimulation of the dorsal column The locations of marks where STT cells were recorded and by mechanical stimulation of the hindlimb. The are shown in Figure 1. Because most of the cells were thalamic electrode was then used to activate STT cells tested with both amines and peptides, the recording spots antidromically (Trevino et al., 1973). In spinalized ani- from all experiments described in this and the following mals, lumbar dorsal horn neurons were activated anti- paper (Willcockson et al., 1984) are condensed into one dromically by surface stimulation of the contralateral figure. Not every recording site was marked, often be- lateral column at a high cervical level. The dorsal column cause several cells were in close proximity to each other. was interrupted caudal to this stimulation site to prevent Most of the recordings were made in laminae I and V, volleys in the dorsal columns from activating STT cells where STT cells projecting to the VPLc nucleus are most orthodromically (cf. Foreman et al., 1976). STT cells concentrated (Willis et al., 1974). were classified according to their responses to innocuous A total of 48 STT cells in 16 different animals were or noxious mechanical stimuli applied to the receptive tested with biogenic amines. Cell depths ranged from 400 field (Chung et al., 1979). In experiments with spinalized to 2070 pm, and antidromic thresholds were 20 to 600 animals, antidromically activated dorsal horn cells were PA.
Load more

Recommended publications
  • Muscle Relaxants Femoral Arteriography.,,>
    IN THIS ISSUE: , .:t.i ". Muscle Relaxants fI, \'.' \., Femoral ArteriographY.,,> University of Minnesota Medical Bulletin Editor ROBERT B. HOWARD, M.D. Associate Editors RAY M. AMBERG GILBERT S. CAMPBELL, M.D. ELLIS S. BENSON, MD. BYRON B. COCHRANE, M.D. E. B. BROWN, PhD. RICHARD T. SMITH, M.D. WESLEY W. SPINK, MD. University of Minnesota Medical School J. 1. MORRILL, President, University of Minnesota HAROLD S. DIEHL, MD., Dean, College of Medical SciencBs WILLIAM F. MALONEY, M.D., Assistant Dean N. 1. GAULT, JR., MD., Assistant Dean University Hospitals RAY M. AMBERG, Director Minnesota Medical Foundation WESLEY W. SPINK, M.D., President R. S. YLVISAKER, MD., Vice-President ROBERT B. HOWARD, M.D., Secretary-Treasurer Minnesota Medical Alumni Association BYRON B. COCHRANE, M.D., President VIRGIL J. P. LUNDQUIST, M.D., First Vice-President SHELDON M. LAGAARD, MD., Second Vice-President LEONARD A. BOROWICZ, M.D., Secretary JAMES C. MANKEY, M.D., Treasurer UNIVERSITY OF MINNESOTA Medical Bulletin OFFICIAL PUBLICATION OF THE UNIVERSITY OF MINNESOTA HOSPITALS, MINNE· SOTA MEDICAL FOUNDATION, AND MINNESOTA MEDICAL ALUMNI ASSOCIATION VOLUME XXVIII December 1, 1956 NUMBER 4 CONTENTS STAFF MEETING REPORTS Current Status of Muscle Relaxants BY J. Albert Jackson, MD., J. H. Matthews, M.D., J. J. Buckley, M.D., D.S.P. Weatherhead, M.D., AND F. H. Van Bergen, M.D. 114 Small Vessel Changes in Femoral Arteriography BY Alexander R. Margulis, M.D. AND T. O. Murphy, MD.__ 123 EDITORIALS .. - -. - ---__ __ _ 132 MEDICAL SCHOOL ACTIVITIES ----------- 133 POSTGRADUATE EDUCATION - 135 COMING EVENTS 136 PIIb1ished semi.monthly from October 15 to JUDe 15 at Minneapolis, Minnesota.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Cellular Changes in Injured Rat Spinal Cord Following Electrical Brainstem Stimulation
    brain sciences Article Cellular Changes in Injured Rat Spinal Cord Following Electrical Brainstem Stimulation Walter J. Jermakowicz 1,* , Stephanie S. Sloley 2, Lia Dan 2, Alberto Vitores 2, Melissa M. Carballosa-Gautam 2 and Ian D. Hentall 2 1 Department of Neurological Surgery, University of Miami, 1095 NW 14th Terr, Miami, FL 33136, USA 2 Miami Project to Cure Paralysis, University of Miami, 1095 NW 14th Terr., Miami, FL 33136, USA; [email protected] (S.S.S.); [email protected] (L.D.); [email protected] (A.V.); [email protected] (M.M.C.-G.); [email protected] (I.D.H.) * Correspondence: [email protected]; Tel.: +1-615-818-3070 Received: 6 May 2019; Accepted: 27 May 2019; Published: 28 May 2019 Abstract: Spinal cord injury (SCI) is a major cause of disability and pain, but little progress has been made in its clinical management. Low-frequency electrical stimulation (LFS) of various anti-nociceptive targets improves outcomes after SCI, including motor recovery and mechanical allodynia. However, the mechanisms of these beneficial effects are incompletely delineated and probably multiple. Our aim was to explore near-term effects of LFS in the hindbrain’s nucleus raphe magnus (NRM) on cellular proliferation in a rat SCI model. Starting 24 h after incomplete contusional SCI at C5, intermittent LFS at 8 Hz was delivered wirelessly to NRM. Controls were given inactive stimulators. At 48 h, 5-bromodeoxyuridine (BrdU) was administered and, at 72 h, spinal cords were extracted and immunostained for various immune and neuroglial progenitor markers and BrdU at the level of the lesion and proximally and distally.
    [Show full text]
  • Opioid-Sensitive Brainstem Neurons Separately Modulate Pain and Respiration
    OPIOID-SENSITIVE BRAINSTEM NEURONS SEPARATELY MODULATE PAIN AND RESPIRATION By Daniel R. Cleary A DISSERTATION Presented to the Neuroscience Graduate Program and the Oregon Health & Science University School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy June, 2012 School of Medicine Oregon Health & Science University CERTIFICATE OF APPROVAL _______________________________ This is to certify that the PhD dissertation of Daniel R. Cleary has been approved ____________________________________ Mentor : Mary M. Heinricher, PhD ____________________________________ Committee Chair: Michael C. Andresen, PhD ____________________________________ Member: Nabil J. Alkayed, MD, PhD ____________________________________ Member: Michael M. Morgan, PhD ____________________________________ Member: Shaun F. Morrison, PhD ____________________________________ Member: Susan L. Ingram, PhD TABLE OF CONTENTS Table of contents i List of figures and tables vii List of abbreviations ix Acknowledgements xi Abstract xiii Chapter 1. Introduction 1 1.1 Overview 2 1.2 Rostral ventromedial medulla and the maintenance of homeostasis 3 1.2.1 Convergence of pain modulation and homeostasis 3 1.2.2 Anatomy of brainstem modulation 4 1.2.2.1 RVM in the modulation of nociception 5 1.2.2.2 Respiratory modulation by raphe nuclei 5 1.2.2.3 Thermoregulation via raphe nuclei 7 1.2.2.4 Cardiovascular regulation 8 1.2.3 Specificity of function of RVM neurons 9 1.3 Modulation of pain in the maintenance of homeostasis 9 1.3.1 Anatomy of
    [Show full text]
  • Clinical Pharmacokinetics of Muscle Relaxants
    i ,I .. / ,""- Clinical Pharmacokinetics 2: 330-343 (1977) © ADIS Press 1977 Clinical Pharmacokinetics of Muscle Relaxants L.B. Wingard and DR. Cook Departments of Pharmacology and Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania SUl1lmary Muscle relaxants are commonly used as an adjunct to general anaesthesia and to facilitate ventilator care in the intensive care unit. The muscle relaxants are unique in that the degree of neurol1luscular blockade can be directly measured. Thus, for some of the muscle relaxants it is possible to correlate the degree of neuromuscular blockade with the plasma concentration of drug. This quantilalive pllGrmacokinelic approach has been applied primarily to d­ tubocurarine and to a lesser extent to suxamethonium (succinylcholine), gallamine and pan­ curoniul1l. The pharl1lacokinetic information for the other relaxants is mostly descriptive and incomplete. The variation in drug concentration over time is in.fluenced by the distribution, metabolism and excretion of drug. Metabolism by plasma cholinesterase plays a maJor role in the termina­ tion (~f action of suxamethonium. Although pancuronium is partly metabolised its major metabolites have moderate pharmacological activity. The other relaxants are excreted through the kidney. For gallamine and dimethyl-tubocurarine, renal excretion appears to be the only means qf eliinination. However, biliary excretion probably provides an alternative route of elimination for d-tubocurarine and pancuronium. In patients with impaired renal function the duration qf neuromusClilar blockade may be markedly prolonged following standard doses of gallamine or dimethyl-tubocurarine, may be slightly prolonged following standard doses of pancumnium, and is near normal following standard doses qf d-tubocurarine. Following large or repeated doses q(pancuronium or d-tubocurarine, the duration q{ neuromuscular blockade may be markedly prolonged.
    [Show full text]
  • Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19
    Supplemental Information Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi1,2,¶, Koichi Watashi1,2,3,4*, Wakana Saso1,5.6,¶, Kaho Shionoya1,2, Shoya Iwanami7, Takatsugu Hirokawa8,9,10, Tsuyoshi Shirai11, Shigehiko Kanaya12, Yusuke Ito7, Kwang Su Kim7, Kazane Nishioka1,2, Shuji Ando13, Keisuke Ejima14, Yoshiki Koizumi15, Tomohiro Tanaka16, Shin Aoki16,17, Kouji Kuramochi2, Tadaki Suzuki18, Katsumi Maenaka19, Tetsuro Matano5,6, Masamichi Muramatsu1, Masayuki Saijo13, Kazuyuki Aihara20, Shingo Iwami4,7,21,22,23, Makoto Takeda24, Jane A. McKeating25, Takaji Wakita1 1Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 2Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, 3Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan, 4MIRAI, JST, Saitama 332-0012, Japan, 5The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, 6AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 7Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, 8Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan, 9Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan, 10Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan, 11Faculty of Bioscience, Nagahama Institute
    [Show full text]
  • Inputs to Serotonergic Neurons Revealed by Conditional Viral Transneuronal Tracing
    The Journal of Comparative Neurology 514:145–160 (2009) Research in Systems Neuroscience Inputs to Serotonergic Neurons Revealed by Conditional Viral Transneuronal Tracing 1 2 1 JOA˜ O M. BRAZ, * LYNN W. ENQUIST, AND ALLAN I. BASBAUM 1Departments of Anatomy and Physiology and W.M. Keck Foundation Center for Integrative Neuroscience, University of California San Francisco, San Francisco, California 94158 2Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544 ABSTRACT the dorsal raphe (DR) and the nucleus raphe magnus of the Descending projections arising from brainstem serotoner- rostroventral medulla (RVM). Among these are several cat- gic (5HT) neurons contribute to both facilitatory and inhibi- echolaminergic and cholinergic cell groups, the periaque- tory controls of spinal cord “pain” transmission neurons. ductal gray, several brainstem reticular nuclei, and the nu- Unclear, however, are the brainstem networks that influ- cleus of the solitary tract. We conclude that a brainstem 5HT ence the output of these 5HT neurons. To address this network integrates somatic and visceral inputs arising from question, here we used a novel neuroanatomical tracing various areas of the body. We also identified a circuit that method in a transgenic line of mice in which Cre recombi- arises from projection neurons of deep spinal cord laminae nase is selectively expressed in 5HT neurons (ePet-Cre V–VIII and targets the 5HT neurons of the NRM, but not of mice). Specifically, we injected the conditional pseudora- the DR. This spinoreticular pathway constitutes an anatom- bies virus recombinant (BA2001) that can replicate only in ical substrate through which a noxious stimulus can acti- Cre-expressing neurons.
    [Show full text]
  • Neuromodulation in Treatment of Hypertension by Acupuncture: a Neurophysiological Prospective
    Vol.5, No.4A, 65-72 (2013) Health http://dx.doi.org/10.4236/health.2013.54A009 Neuromodulation in treatment of hypertension by acupuncture: A neurophysiological prospective Peyman Benharash1, Wei Zhou2* 1Division of Cardiothoracic Surgery, University of California, Los Angeles, USA 2Department of Anesthesiology, University of California, Los Angeles, USA; *Corresponding Author: [email protected] Received 28 February 2013; revised 30 March 2013; accepted 6 April 2013 Copyright © 2013 Peyman Benharash, Wei Zhou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT study the effects of acupuncture on the hyper- tensive man. Hypertension is a major public health problem affecting over one billion individuals worldwide. Keywords: Central Nervous System; This disease is the result of complex interac- Electroacupuncture; Neurotransmitter; Brain Stem tions between genetic and life-style factors and the central nervous system. Sympathetic hyper- activity has been postulated to be present in 1. INTRODUCTION most forms of hypertension. Pharmaceutical Hypertension has become a serious public health prob- therapy for hypertension has not been perfected, lem impacting over one billion lives worldwide [1]. At often requires a multidrug regimen, and is as- the turn of this century, 7.6 million deaths were attribut- sociated with adverse side effects. Acupuncture, able to hypertension. The majority of this disease burden a form of somatic afferent nerve stimulation has occurred in working people in low to middle-income been used to treat a host of cardiovascular dis- countries, while its prevalence increases with age and the eases such as hypertension.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Pharmacological Review of Chemicals Used for the Capture of Animals
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Proceedings of the 7th Vertebrate Pest Vertebrate Pest Conference Proceedings Conference (1976) collection March 1976 PHARMACOLOGICAL REVIEW OF CHEMICALS USED FOR THE CAPTURE OF ANIMALS Peter J. Savarie U.S. Fish and Wildlife Service Follow this and additional works at: https://digitalcommons.unl.edu/vpc7 Part of the Environmental Health and Protection Commons Savarie, Peter J., "PHARMACOLOGICAL REVIEW OF CHEMICALS USED FOR THE CAPTURE OF ANIMALS" (1976). Proceedings of the 7th Vertebrate Pest Conference (1976). 41. https://digitalcommons.unl.edu/vpc7/41 This Article is brought to you for free and open access by the Vertebrate Pest Conference Proceedings collection at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Proceedings of the 7th Vertebrate Pest Conference (1976) by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. PHARMACOLOGICAL REVIEW OF CHEMICALS USED FOR THE CAPTURE OF ANIMALS* PETEIR J. SAVARIE, U.S. Fish and Wildlife Service, Building 16, Federal Center, Denver, Colorado 80225 ABSTRACT: A review of the literature reveals that over 60 chemicals have been used for the capture of wi l d animals, but only 30 of the most widely used chemicals are discussed in the present paper. For practical considerations these chemicals can be c l a ssified as being either (l) neuromuscular blocking agents, or (2) central nervous system (CNS) depressants. Some common neuromuscular blocking agents are d-tubocurarine, gallamine, succiny1choline, and nicotine. M99 and its derivatives, phencyclidine, and xylazine are some of the more commonly used CNS depressants. Neuromuscular blocking agents have a relatively rapid onset and short duration of action but they do not possess sedative, analgesic, or anesthetic properties.
    [Show full text]
  • PRODUCT MONOGRAPH TRACRIUM7 (Atracurium Besylate)
    PRODUCT MONOGRAPH TRACRIUM7 (Atracurium besylate) 10 mg/mL Injection Intravenous Skeletal Neuromuscular Blocking Agent AbbVie Corporation DATE OF PREPARATION: 8401 Trans Canada Highway November 1, 2012 St-Laurent (QC) CANADA H4S 1Z1 DATE OF LATEST REVISION: DATE OF REVISION: Control No. 158344 NOTE: TRACRIUM is a trademark of the Glaxo group of companies, AbbVie Corporation licensed use - 2 - PRODUCT MONOGRAPH NAME OF DRUG TRACRIUM7 (Atracurium Besylate Injection) THERAPEUTIC CLASSIFICATION Intravenous Skeletal Neuromuscular Blocking Agent ACTIONS AND CLINICAL PHARMACOLOGY TRACRIUM (atracurium besylate) is a nondepolarizing, intermediate-duration, skeletal neuromuscular blocking agent. Nondepolarizing agents antagonize the neurotransmitter action of acetylcholine by binding competitively to cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed by acetylcholinesterase inhibitors such as neostigmine, edrophonium and pyridostigmine. The duration of neuromuscular blockade produced by atracurium besylate is approximately one-third to one-half the duration seen with d-tubocurarine, metocurine and pancuronium at equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing atracurium besylate doses. INDICATIONS AND CLINICAL USE TRACRIUM (atracurium besylate) is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. CONTRAINDICATIONS TRACRIUM (atracurium besylate) is contraindicated in patients known to have a hypersensitivity to atracurium. Use of atracurium from multiple-dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known sensitivity to benzyl alcohol.
    [Show full text]
  • Enkephalin Systems in Diencephalon and Brainstem of the Rat
    THE JOURNAL OF COMPARI1TIVE NEUROLOGY 220:310-320 (19113) Enkephalin Systems in Diencephalon and Brainstem of the Rat HENRY KHACHATURIAN, MICHAEL E. LEWIS, AND STANLEY J. WATSON Mental Health Research Institute, University of Michigan, Ann Arbor, Michigan 48105 ABSTRACT The immunocytochemical distribution of [Leulenkephalin and an adre- nal enkephalin precursor fragment (BAM-22P)immunoreactivity was inves- tigated in the diencephalon and brainstem of rats pretreated with relatively high doses of colchicine (300-400 pgil0 pl intracerebroventricularly). The higher ranges of colchicine pretreatment allowed the visualization of exten- sive enkephalincontaining systems in these brain regions, some of which are reported for the first time. Immunoreactive perikarya were found in many hypothalamic and thalamic nuclei, interpeduncular nucleus, substan- tia nigra, the colliculi, periaqueductal gray, parabrachial nuclei, trigeminal motor and spinal nuclei, nucleus raphe magnus and other raphe nuclei, nu- cleus reticularis paragigantocellularis, vestibular nuclei, several nor- adrenergic cell groups, nucleus tractus solitarius, as well as in the spinal cord dorsal horn. In addition to the above regions, immunoreactive fibers were also noted in the habenular nuclei, trigeminal sensory nuclei, locus coeruleus, motor facial nucleus, cochlear nuclei, dorsal motor nucleus of the vagus, and hypoglossal nucleus. When adjacent sections to those stained for Peulenkephalin were processed for BAM-22P immunoreactivity, it was found that these two immunoreactivities were distributed identically at almost all anatomical locations. BAM-22P immunoreactivity was generally less pronounced and was preferentially localized to neuronal perikarya. The results of the present as well as the preceding studies (Khachaturian et al., '83) strongly suggest substantial structural similarity between the adrenal proenkephalin precursor and that which occurs in the brain.
    [Show full text]